Table 4.
Prognostic factors in patients in groups 1, 2, 7.
| Multivariate Analysis | ||
|---|---|---|
| p-Value | Hazard Ratio (95%CI) | |
| Female sex | 0.16 | 0.81 (0.60–1.09) |
| Age, ≥75 years old | 0.10 | 1.29 (0.98–1.75) |
| Group7 (vs. group 1or 2) | <0.01 | 0.36 (0.17–0.78) |
| IPMN-derived carcinoma (vs. PDAC) | 0.13 | 0.49 (0.19–1.22) |
| BMI (kg/mm2) ≥18.5 | <0.01 | 0.60 (0.42–0.87) |
| CA19-9 (U/mL) ≥425 | <0.001 | 1.69 (1.24–2.30) |
| NLR ≥ 3.6 | <0.01 | 1.58 (1.18–2.11) |
Group 1 and 2 included patients with pancreatic cancer (PC) identified through symptoms of biliary obstruction symptoms and symptoms that were not in group 1, respectively. Group 7 included patients with PC identified through abdominal ultrasonography during medical checkup of asymptomatic individuals. Statistical analysis was performed using Cox regression hazard model. The value of CA19-9, 425 (U/mL) and NLR, 3.5, was based on the median value of patients in groups 1, 2, and 7. IPMN: intraductal papillary mucinous neoplasm, PDAC: pancreatic ductal adenocarcinoma, BMI: body mass index, CA19-9: serum level of carbohydrate antigen 19-9, NLR: neutrophil to lymphocyte ratio, CI: confidence intervals.